Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Gut Bacteria Linked to Stroke, Epilepsy Risk

By Kenny Walter | May 18, 2017

Bacteria in the gut might be leading to problems with the blood vessels in the brain.

Researchers from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institute of Health (NHI), have found that the microbes in the intestines might lead to malformations that can cause strokes or epilepsy.

 Cerebral cavernous malformations (CCMs)—clusters of dilated, thin-walled blood vessels—can lead to seizures or stroke when blood leaks into the surrounding blood tissue.

“This study is exciting because it shows that changes within the body can affect the progression of a disorder caused by a genetic mutation,” Jim Koenig, Ph.D., program director at NINDS, said in a statement.

After investigating the mechanisms that cause the lesions in genetically engineered mice, the researchers discovered the link to the intestinal bacteria and after eliminating the bacteria, they were able to reduce the lesions.

“It was a complete mystery. Suddenly, our normally reliable mouse model was no longer forming the lesions that we expected,” Dr. Mark Kahn, professor of medicine at the University of Pennsylvania and senior author of the study, said in a statement. “What’s interesting is that this variability in lesion formation is also seen in humans, where patients with the same genetic mutation often have dramatically different disease courses.”

The researchers found that during experiments the few mice that continued to form lesions had developed bacterial abscesses in their abdomens containing Gram-negative bacteria. About half of the mice developed significant malformations after similar bacterial infections were deliberately induced in the CCM model mice.

“The mice that formed CCMs also had abscesses in their spleens, which meant that the bacteria had entered the bloodstream from the initial abscess site,” Alan Tang, a graduate student in Kahn’s lab, said in a statement. “This suggested a connection between the spread of a specific type of bacteria through the bloodstream and the formation of these blood vascular lesions in the brain.”

According to the researchers, gram-negative bacteria produces the molecule lipopolysaccharides (LPS) that are potent activators of innate immune signaling and influence blood vessel behavior in the brain. When the mice only received LPS, they formed numerous large CCMs while when TLR4—the LPS receptor—was removed the lesions no longer formed.

“We knew that lesion formation could be driven by Gram-negative bacteria in the body through LPS signaling,” Kahn said. “Our next question was whether we could prevent lesions by changing the bacteria in the body.”

According to the study, the study identified the roles of the microbiome and innate immune signaling in the pathogenesis of a cerebrovascular disease, as well as strategies for treatment.

The study was published in Nature.

Related Articles Read More >

New dangers in the woods — and the hope that research offers us
Novel mass spectrometry solution simplifies insight gathering into macromolecular complexes
ENPICOM launches display solution to accelerate antibody selection while maximizing precision
Thermo Fisher Scientific autoimmune-testing instruments now available in the U.S.
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars